Testing and Diagnostics Library
Every article, presentation, spotlight, and news item we've tagged to Testing and Diagnostics.
Showing 25–48 of 331
AI-Driven Early Disease Detection Shifts Prevention Timeline
Function and NYU Grossman School of Medicine are combining clinical datasets with multimodal health-monitoring data to develop AI models for earlier detection of cancer, cognitive decline, and cardiometabolic disease. This partnership represents a shift toward predictive signal detection—identifying disease markers before clinical presentation rather than after symptom onset.
Epigenetic Methylation Maps Cardiovascular Aging Beyond Cholesterol
MyHeartCode uses DNA methylation analysis across millions of genomic sites to assess cardiovascular aging and metabolic function over a three- to four-month window, offering a dynamic biological picture beyond single-point cholesterol measurement. This approach addresses a critical gap for individuals with family history of heart disease or prior cardiovascular events—populations for whom conventional lipid panels provide insufficient insight into underlying disease trajectory.
OMICmAge is a multiomic biological aging clock using electronic medical records
Researchers developed OMICmAge, a DNA-methylation-based biological aging clock integrating proteomic and metabolomic data from 31,000 electronic medical records. The measure predicts mortality and age-related disease risk with performance comparable to or superior to existing biomarkers, offering a scalable tool for quantifying biological aging status.
Biological Age Clocks Face a Public Health Validation Test
Abu Dhabi's Public Health Centre has entered a two-year agreement with Ultrahuman to build and clinically validate a Biological Health Age model that merges laboratory biomarkers with continuous wearable data on cardiovascular function, sleep, metabolism and recovery. The stated aim is earlier identification of chronic disease trajectories, which would require the measure to outperform conventional risk tools such as blood pressure and lipid panels. For longevity medicine, the project tests an assumption the field has largely accepted without proof: that biological age can be measured accurately enough, at population scale, to alter clinical decisions.
Life Time brings VO₂ max and metabolic testing to the masses
Life Time's nationwide rollout of SpiroFit metabolic testing brings laboratory-grade VO₂ max and fuel-utilization data into mainstream fitness clubs, enabling members to identify metabolic inflection points and train with precision rather than assumption. This democratization of metabolic testing shifts a central longevity marker—previously available only to elite athletes—into accessible measurement for the general population.
Glycan aging signals reveal lysosomal decline across organs
Age-related changes in protein glycosylation patterns across organs correlate with declining lysosomal enzyme function, suggesting that impaired cellular waste processing contributes to aging phenotypes. This connection between glycan metabolism and lysosomal capacity identifies a mechanistic link in how cells lose their ability to maintain homeostasis over time.
Epigenetic clocks fail real-world reliability test
Epigenetic clocks measure biological age consistently in the laboratory but fluctuate significantly in response to daily physiological events, undermining their clinical utility. This technical-biological gap means most current clocks cannot reliably predict health outcomes or track intervention effects in real-world conditions.
Whole Genome Sequencing Redefines Preventive Health at $599
Clinical-grade whole genome sequencing at $599 represents a threshold moment for genomics in preventive healthcare, moving from exclusive research tool to mass-market accessibility. The service sequences all 6.4 billion DNA base pairs and delivers continuously updated interpretations as scientific understanding evolves, potentially shifting how individuals decode inherited disease risks and medication responses.
Exercise and Biological Age: Association Outpaces Evidence
Physical activity correlates with lower biological age as measured by DNA methylation clocks (Horvath and GrimAge), but existing evidence is predominantly cross-sectional, preventing definitive causal claims. Longitudinal studies are needed to establish dose-response relationships and whether activity can meaningfully alter aging trajectories.
Reproductive life events and biological aging in women over 50: evidence from DNA methylation clocks
Reproductive life events—including age at menarche, menopause timing, and pregnancy history—correlate with biological aging rates in women over 50, as measured by DNA methylation clocks. These associations suggest that hormonal exposure patterns across the lifespan accumulate physiological debt that manifests as measurable differences in aging velocity.
Sex-specific biological aging: 21-system assessment beyond composite scores
Generation Lab has introduced SystemAge, an at-home biological age assessment platform that evaluates aging across 21 body systems with sex-specific calibration, moving away from single composite scores. The approach incorporates lifestyle factors—walking quality, travel-related stress, sleep adaptation—as measurable drivers of aging rate, grounding longevity testing in modifiable behaviors rather than static biomarker snapshots alone.
Epigenetic aging and cancer incidence in a German cohort of older adults
Epigenetic age acceleration—measured through DNA methylation patterns—independently predicts cancer incidence in older adults, even after accounting for chronological age and established risk factors. This biomarker offers a quantifiable proxy for biological aging that may identify individuals at elevated cancer risk before conventional screening protocols would.
#386 – Aging clocks—what they measure, how they work, and their clinical and real-world relevance
Aging clocks are biomarkers that quantify biological age independent of chronological time, offering a measurable framework to evaluate whether interventions actually slow aging. Their clinical utility depends on validating what they measure, understanding their mechanisms, and establishing whether changes in these markers correlate with meaningful health outcomes.
Aging Clocks Compared Head-to-Head in Six-Month Cohort
A six-month competition hosted by NeuroAge Therapeutics with TruDiagnostic, Vero Bioscience, Harvard FaceAge and collaborating academic labs will measure participants across epigenetic, proteomic, imaging, facial and functional age markers, then repeat the identical panel after a self-directed intervention period. Because every entrant receives the same multi-modal battery, the design produces rare side-by-side data on whether independent aging clocks agree with one another and whether they move in response to behavior change. Awards recognize both the largest reduction in measured biological age and the lowest biological age relative to chronological age.
AI-Driven Dementia Detection at Specialist Scale
Agentic AI systems capable of continuous learning across patient data may enable specialist-level dementia diagnosis and care at scale, addressing the critical gap between neurodegenerative disease prevalence and available expertise. This approach integrates human-AI collaboration to reason across complex clinical datasets in ways that improve diagnostic accuracy and treatment planning.
Early Disease Detection Through AI Pattern Recognition in Aging
A collaboration between Insilico Medicine and Human Longevity aims to develop an AI foundation model capable of detecting disease years or decades before symptom onset by identifying subtle biological patterns in aging. The approach represents a shift from reactive treatment toward earlier intervention—a fundamental reorientation of how medicine identifies risk.
OMICmAge quantifies biological age by integrating multi-omics with electronic medical records
OMICmAge integrates multi-omics data with DNA methylation to create a biological age measure that predicts disease and mortality risk more accurately than chronological age alone. This approach enables risk stratification based on measurable molecular signatures rather than calendar years.
Whole Genome Sequencing at Clinical Grade for $599
Human Longevity Inc. launched Genomics for All, a $599 whole genome sequencing test that delivers clinical-grade results via AI interpretation without requiring a clinic visit. The product identifies disease risk across 10,000+ genetic variants, flags medication response markers, and provides AI-powered reanalysis as new research emerges.
DeepStrataAge: an interpretable deep-learning clock that reveals stage- and sex-divergent DNA methylation aging dynamics
DeepStrataAge, a deep-learning model trained on DNA methylation patterns, identifies distinct aging trajectories between biological sexes and developmental stages, revealing that aging acceleration is not uniform across the lifespan. This sex- and stage-specific resolution improves the precision of biological age assessment and may refine risk stratification for age-related disease prevention.
sc-ChromAging: A Single-Cell Chromatin Accessibility-based Clock Decodes Cell-Type-Specific Epigenetic Aging Trajectories
Researchers developed sc-ChromAging, a single-cell epigenetic clock that measures aging at the cellular level by analyzing chromatin accessibility patterns specific to each cell type. This tool reveals that different cells age at different rates and through distinct molecular pathways, offering a method to detect and potentially intervene in age-related cellular dysfunction before systemic decline occurs.
SpectraCell packages longevity, early disease detection in one kit
SpectraCell's Baseline Nexus bundles four diagnostic tests—micronutrient status, lipoprotein particle profiling, telomere length, and MTHFR genotyping—into a single assessment designed to identify subclinical dysfunction before it progresses to clinical disease. The package reframes preventive diagnostics by measuring intracellular nutrient utilization and biological aging markers alongside conventional cardiovascular risk factors, enabling earlier intervention at the stage where metabolic and inflammatory processes are still modifiable.
SpectraCell launches Baseline Nexus longevity and risk test
SpectraCell introduced Baseline Nexus, a comprehensive assessment measuring intracellular micronutrient status, lipoprotein profiles, telomere length, and genetic variants through metabolically active lymphocytes rather than serum analytes alone. The test targets early detection of functional cellular deficits that compromise immune function and metabolic capacity—both determinants of health trajectory and aging rate.
AI Tool Sets New Standard in Diagnosing Rare Diseases
DeepRare, a multi-agent AI system combining large language models with specialized diagnostic tools, demonstrated superior performance in identifying rare diseases compared to other digital tools and human physicians. The system addresses a critical clinical problem: patients with rare diseases wait an average of 5+ years for diagnosis, enduring repeated misdiagnoses and unnecessary interventions.
NMR Blood Analysis Reveals Particle Patterns Behind Cardiometabolic Risk
Nuclear magnetic resonance (NMR) spectroscopy of blood plasma provides simultaneous measurement of lipoprotein particle number, size distribution, and metabolic markers—enabling assessment of cardiovascular disease risk, insulin resistance, inflammatory status, and mortality risk from a single sample. This integrated approach captures mechanistic information about metabolic dysfunction that standard lipid panels miss, offering a more precise foundation for risk stratification and therapeutic decision-making.